Relmada Therapeutics (RLMD) Tops Q4 EPS by 3c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Investing.com’s stocks of the week
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results